Purpose: Secretory phospholipase A(2) group IIA (sPLA(2-)IIA) concentration and activity are associated with increased risk of cardiovascular events in acute coronary syndrome (ACS) patients. This study evaluated baseline differences in sPLA(2)-IIA concentration and other inflammatory markers in ACS patients with and without diabetes, and the inflammatory biomarker response to selective sPLA(2) inhibition.
Methods: The effects of the sPLA(2) inhibitor varespladib methyl 500 mg daily and placebo on serial changes in inflammatory and lipid biomarkers were examined in 624 ACS patients who were treated with standard of care including atorvastatin 80 mg daily.
Results: Compared with non-diabetic patients, diabetic patients had higher baseline concentrations of sPLA(2)-IIA (p = 0.0066), hs-CRP (p = 0.0155), and IL-6 (p = 0.009). At 8 weeks of treatment (primary endpoint), varespladib methyl reduced median sPLA(2)-IIA levels by -83.6% in diabetic patients and by -82.4% in non-diabetic patients (p = 0.33). Median hs-CRP and IL-6 levels were reduced in both varespladib methyl-treated diabetic and non-diabetic patients, but these differences were not statistically significantly different at 8 weeks (p = 0.57 and p = 0.97 respectively).
Conclusions: Varespladib significantly reduces the post-ACS inflammatory response in those with and without diabetes. These responses were greater in diabetic subjects compared to non-diabetic subjects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10557-011-6344-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial.
BMJ Glob Health
October 2024
Ophirex, Inc, Corte Madera, California, USA.
Article Synopsis
- Snakebite envenoming (SBE) causes over 500,000 deaths or serious injuries annually, and a phase II clinical trial was conducted to evaluate the safety and efficacy of varespladib methyl, an oral treatment, in patients bitten by venomous snakes.
- The trial, which was double-blind and placebo-controlled, enrolled patients in emergency departments in the USA and India, assessing changes in severity of snakebite symptoms using the Snakebite Severity Score (SSS) after treatment.
- Results indicated no significant difference in SSS improvement between the varespladib and placebo groups overall, but early treatment (within 5 hours of the bite) showed potential benefits in illness severity and recovery outcomes.
Oral and IV Varespladib Rescue Experiments in Juvenile Pigs with Weakness Induced by Australian and Papuan Venoms.
Toxins (Basel)
September 2023
Division of Research Ophirex, Inc., Corte Madera, CA 94925, USA.
Article Synopsis
- * In a study with juvenile pigs, varespladib was tested against venom from the Australian and Papuan taipan, showing effectiveness in improving survival rates when administered, particularly when given early.
- * Findings indicate that early treatment is crucial and suggest that varespladib can reverse neurotoxic effects even when given after a delay, supporting ongoing clinical trials for snakebite therapies.
The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming.
Toxins (Basel)
December 2022
Ophirex, Inc., Corte Madera, CA 94295, USA.
Article Synopsis
- - Snakebite poses a serious global health crisis with high rates of sickness and death, and varespladib has been identified as a potential oral treatment to combat snakebite envenoming (SBE) through its mechanism of blocking venom enzymes.
- - The BRAVO study aims to assess the safety and effectiveness of oral varespladib-methyl compared to a placebo, using a randomized, double-blind approach involving patients aged 5 and up with acute SBE.
- - Regulatory approval has been secured for the study in both India and the US, ensuring ethical standards and good clinical practices are followed throughout the trial process.
Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes.
Toxins (Basel)
November 2022
Center for Exploration and Travel Health, California Academy of Sciences, San Francisco, CA 94118, USA.
The availability of effective, reliably accessible, and affordable treatments for snakebite envenoming is a critical and long unmet medical need. Recently, small, synthetic toxin-specific inhibitors with oral bioavailability used in conjunction with antivenom have been identified as having the potential to greatly improve outcomes after snakebite. Varespladib, a small, synthetic molecule that broadly and potently inhibits secreted phospholipase A2 (sPLA2s) venom toxins has renewed interest in this class of inhibitors due to its potential utility in the treatment of snakebite envenoming.
View Article and Find Full Text PDFVarespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations.
Toxicon
October 2021
Department of Pharmacology, Institute of Biological Science, Federal University of Minas Gerais (UFMG), Brazil. Electronic address:
Varespladib (LY315920) is a synthetic phospholipase A (PLA) inhibitor that has been demonstrating antiophidic potential against snake venoms that present PLA neurotoxins. In this study, we evaluate the capacity of Varespladib to inhibit the neuromuscular effects of crotoxin (CTX), the main toxic component of Crotalus durissus terrificus snake venom, and its PLA subunit (CB). We performed a myographic study to compare the neuromuscular effects of CTX or CB and the mixture of these substances plus Varespladib in mice phrenic nerve-diaphragm muscle preparations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!